Please login to the form below

Not currently logged in
Email:
Password:

Abbott's paediatric HIV drug wins FDA approval

US-based pharmaceutical company Abbott wins FDA approval for its lower-strength protease-inhibitor Kaletra, which will be available in the US from November 2007

US-based pharmaceutical company Abbott has won FDA approval for its lower-strength protease-inhibitor Kaletra (lopinavir/ritonavir), which will be available in the US from November 2007.

The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15 kg or more who are able to swallow the intact tablet.

Scott Brun, divisional vice-president of infectious diseases and renal development at Abbott's global pharmaceutical R&D arm, said: "HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world. Abbott developed a lower-strength tablet formulation of Kaletra to give doctors an innovative treatment option to help curb the impact of HIV infection in children."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...